Tamoxifen (Tam) treatment is a first-line endocrine therapy for estrogen receptor-a-positive breast cancer patients. Unfortunately, resistance frequently occurs and is often related with overexpression of the membrane tyrosine kinase receptor HER2. This is the rationale behind combined treatments with endocrine therapy and novel inhibitors that reduce HER2 expression and signaling and thus inhibit Tam-resistant breast cancer cell growth. In this study, we show that activation of farnesoid X receptor (FXR), by the primary bile acid chenodeoxycholic acid (CDCA) or the synthetic agonist GW4064, inhibited growth of Tam-resistant breast cancer cells (termed MCF-7 TR1), which was used as an in vitro model of acquired Tam resistance. Our results demonstrate that CDCA treatment significantly reduced both anchorage-dependent and anchorage-independent epidermal growth factor (EGF)-induced growth in MCF-7 TR1 cells. Furthermore, results from western blot analysis and real-time reverse transcription-PCR revealed that CDCA treatment reduced HER2 expression and inhibited EGFmediated HER2 and p42/44 mitogen-activated protein kinase (MAPK) phosphorylation in these Tam-resistant breast cancer cells. Transient transfection experiments, using a vector containing the human HER2 promoter region, showed that CDCA treatment downregulated basal HER2 promoter activity. This occurred through an inhibition of nuclear factor-jB transcription factor binding to its specific responsive element located in the HER2 promoter region as revealed by mutagenesis studies, electrophoretic mobility shift assay and chromatin immunoprecipitation analysis. Collectively, these data suggest that FXR ligand-dependent activity, blocking HER2/MAPK signaling, may overcome anti-estrogen resistance in human breast cancer cells and could represent a new therapeutic tool to treat breast cancer patients that develop resistance.
Tamoxifen (Tam) treatment is a first-line endocrine therapy for estrogen receptor-a-positive breast cancer patients. Unfortunately, resistance frequently occurs and is often related with overexpression of the membrane tyrosine kinase receptor HER2. This is the rationale behind combined treatments with endocrine therapy and novel inhibitors that reduce HER2 expression and signaling and thus inhibit Tam-resistant breast cancer cell growth. In this study, we show that activation of farnesoid X receptor (FXR), by the primary bile acid chenodeoxycholic acid (CDCA) or the synthetic agonist GW4064, inhibited growth of Tam-resistant breast cancer cells (termed MCF-7 TR1), which was used as an in vitro model of acquired Tam resistance. Our results demonstrate that CDCA treatment significantly reduced both anchorage-dependent and anchorage-independent epidermal growth factor (EGF)-induced growth in MCF-7 TR1 cells. Furthermore, results from western blot analysis and real-time reverse transcription-PCR revealed that CDCA treatment reduced HER2 expression and inhibited EGFmediated HER2 and p42/44 mitogen-activated protein kinase (MAPK) phosphorylation in these Tam-resistant breast cancer cells. Transient transfection experiments, using a vector containing the human HER2 promoter region, showed that CDCA treatment downregulated basal HER2 promoter activity. This occurred through an inhibition of nuclear factor-jB transcription factor binding to its specific responsive element located in the HER2 promoter region as revealed by mutagenesis studies, electrophoretic mobility shift assay and chromatin immunoprecipitation analysis. Collectively, these data suggest that FXR ligand-dependent activity, blocking HER2/MAPK signaling, may overcome anti-estrogen resistance in human breast cancer cells and could represent a new therapeutic tool to treat breast cancer patients that develop resistance.
Introduction
Administration of the selective estrogen receptor (ER) modulator tamoxifen (Tam), to block ERa activity, is still a first-line endocrine therapy for the management of all stages of ERa-positive breast cancer (Fisher et al., 1998; Gradishar, 2004) . Unfortunately, not all patients who have ERa-positive tumors respond to Tam (de novo resistance), and a large number of patients who do respond will eventually develop disease progression or recurrence while on therapy (acquired resistance), limiting the efficacy of the treatment.
Multiple mechanisms are responsible for the development of endocrine resistance. Among these are the loss of ERa expression or function (Encarnacion et al., 1993) , alterations in the balance of regulatory cofactors, increased oncogenic kinase signaling (Blume-Jensen and Hunter, 2001) , and altered expression of growth factor signaling pathways (Arpino et al., 2004; Schiff et al., 2004; Sabnis et al., 2005; Staka et al., 2005) . For instance, several preclinical and clinical studies suggest that both de novo and acquired resistance to Tam in breast cancers can be associated with elevated levels of the membrane tyrosine kinase HER2 (c-ErbB2, Her2/ neu) (Chung et al., 2002; Meng et al., 2004; Shou et al., 2004; Gutierrez et al., 2005) .
The HER2 gene codes for a 185 kDa receptor, a member of the epidermal growth factor receptor (EGFR) family of transmembrane tyrosine kinases, which also includes HER3 and HER4, mainly involved in signal transduction pathways that regulate cell growth and differentiation. This receptor has no ligand of its own, but is activated by hetero-oligomerization with other ligand-activated receptors (Yarden, 2001) . The HER2 gene is amplified and/or overexpressed in 20-25% of ERa-positive breast cancers (Slamon et al., 1989) , and clinical observations indicate that tumors with high levels of HER2 have poor outcome when treated with Tam (Osborne et al., 2003; Kirkegaard et al., 2007) .
The mechanisms by which HER2 overexpression mediates Tam resistance result from an intimate crosstalk between ERa and growth factor receptors kinase cascades, such as Ras/mitogen-activated protein kinase (MAPK) signaling, that in turn can promote growth and progression in breast cancer cells, negating the inhibitory effects of Tam on nuclear ERa activity (Arpino et al., 2008) . HER2 overexpression is not attributed solely to amplification of the HER2 gene copy number, but can also occur from a single-copy gene due to deregulation events at the transcriptional level (Hurst, 2001) .
Thus, an analysis of new mechanisms controlling HER2/neu receptor gene expression could be important to enhance strategies to reverse Tam resistance in breast cancer patients.
Farnesoid X receptor (FXR), a member of the nuclear receptor superfamily of ligand-dependent transcription factors, is mainly expressed in the liver and the gastrointestinal tract, where it regulates expression of genes involved in bile acids, cholesterol and triglyceride metabolism (Forman et al., 1995; Makishima et al., 1999; Parks et al., 1999) . Recently, this receptor was also detected in different non-enterohepatic compartments, including breast cancer tissue and breast cancer cell lines (Bishop-Bailey, 2004; Swales et al., 2006; Journe et al., 2008; Catalano et al., 2010) . For instance, FXR activation inhibits breast cancer cell proliferation and negatively regulates aromatase activity reducing local estrogen production (Swales et al., 2006) , whereas other authors have reported that FXR activation stimulates MCF-7 cell proliferation but only in steroid-free medium (Journe et al., 2008) . However, the functions of FXR in breast cancer tissue are still not completely understood, and there are no data regarding its role in the endocrine-resistant breast cancer phenotype. Thus, we have investigated whether activated FXR may modulate the growth of human MCF-7 Tam-resistant breast cancer cells, a model that was developed to mimic in vitro the occurrence of acquired Tam resistance.
Here, we demonstrate that a specific FXR ligand chenodeoxycholic acid (CDCA) or its synthetic agonist GW4064 inhibited Tam-resistant breast cancer cell proliferation and EGF-induced growth, by reducing expression of the HER2 receptor. This occurs through an FXR-mediated inhibition of nuclear factor (NF)-kB binding on the human HER2 promoter region.
Results

FXR expression in Tam-resistant breast cancer cells
Acquired resistance to Tam has been associated with elevated levels of the membrane tyrosine kinase HER2 (Knowlden et al., 2003; Nicholson et al., 2004; Gutierrez et al., 2005) . In agreement with these reports, we found a marked increase in the levels of total HER2 protein content in Tam-resistant MCF-7 TR1 compared with MCF-7 cells, whereas no differences were seen in the expression of EGFR and ERa (Figure 1a) . We therefore evaluated anchorage-independent growth of MCF-7 and MCF-7 TR1 cells after treatment with herceptin, a humanized monoclonal antibody directed against the extracellular domain of HER2, in the presence or not of EGF. Herceptin had no effect on MCF-7 growth, whereas significantly inhibited anchorage-independent growth of MCF-7 TR1 cells in basal conditions as well as upon EGF treatment (Figure 1b) . These data confirm that the HER2 overexpression found in the MCF-7 TR1 cells renders them more sensitive to the inhibitory effect of this selective HER2-targeted agent.
Next, we evaluated the expression of FXR in MCF-7 and MCF-7 TR1 cells. Our results revealed the presence of FXR mRNA (Figure 1c , upper panel) and protein ( Figure 1c , lower panel) in both MCF-7 and MCF-7 TR1 cells. To assess the ability of FXR to be transactivated by CDCA, we transiently transfected cells with an FXR-responsive reporter gene (FXRE-IR1) followed by treatment with increasing doses of CDCA. The specificity of the system was tested by co-transfecting the cells with a dominant negative FXR (FXR-DN) plasmid. As shown in Figure 1d , CDCA treatment induced a dose-dependent FXR activation in both cell lines and expression of the FXR-DN completely abrogated the CDCA-induced transactivation.
FXR activation inhibits Tam-resistant breast cancer cell growth We examined, by MTT growth assays, the effects of increasing doses of CDCA and GW4064. Treatment with both ligands reduced cell proliferation in a dosedependent manner in MCF-7 and MCF-7 TR1 cells, whereas had no effects on normal breast epithelial cells MCF-10A (Figures 2a and b) . Similar results in growth inhibition were also obtained in another Tam-resistant breast cancer cell line termed MCF-7 TR2 (Supplementary Figures 2a and b) . It is worth noting that the inhibitory effects exerted by FXR ligands on cell proliferation were significant at lower dose in MCF-7 TR1 cells compared with MCF-7 cells, as evidenced by half-maximal inhibitory concentration (IC 50 ) values (Table 1 ). The antiproliferative effects exerted by CDCA were completely reversed in the presence of a FXR-DN plasmid, supporting the specific involvement of the FXR (Figure 2c ).
Next, we tested the effects of CDCA in the presence of Tam on cell growth ( Figure 2d ). As expected, with anti-estrogen treatment, cell viability was significantly reduced in MCF-7 cells, whereas MCF-7 TR1 cells growth was unaffected, confirming the Tam-resistant phenotype. Interestingly, combined treatment with CDCA and Tam reduced growth of MCF-7 TR1 cells compared with treatment with Tam alone, but showed no additive effects in MCF-7 cells (Figure 2d ). The ability of CDCA and Tam to inhibit Tam-resistant growth was also confirmed using anchorage-independent growth assays (Figure 2e ). These results suggest that FXR activation can interfere with the cellular mechanisms by which MCF-7 TR1 cells escape antihormonal treatments.
CDCA reduces HER2 expression and signaling in MCF-7 TR1 cells To understand the mechanisms associated with CDCAmediated inhibition of Tam-resistant growth in breast cancer cells, we evaluated the possible role of FXR ligands in modulating HER2 expression. As shown in Figure 3a , treatment with CDCA downregulated HER2 protein expression in both cell lines, but with higher reduction seen in MCF-7 TR1 cells. Similar results were also observed after treatment with GW4064 (data not shown). A reduction in HER2 levels was also found upon CDCA treatment in MCF-7 TR2 cells (Supplementary Figure 2c ). No differences were found in EGFR expression upon CDCA treatment (Supplementary Figure 3 ), confirming that activated FXR specifically target HER2 expression in breast cancer cells. In the presence of an FXR-DN the HER2 downregulation was completely abrogated, confirming FXR involvement in CDCA-induced effects on HER2 (Figure 3b ). Next, we questioned whether these HER2-decreased levels could modify the responsiveness of breast cancer cells after growth factor stimulation. Thus, we investigated the effects of short-term stimulation with EGF, in the presence of CDCA treatment, on phosphorylation levels of HER2 and MAPK, the main downstream effectors of the growth factor signaling. EGF treatment increased phosphorylation of both HER2 and MAPK, even though in higher extent in MCF-7 TR1 cells. However, pretreatment with CDCA reduced EGFinduced phosphorylation of HER2 in both cell lines and drastically prevented MAPK activation in MCF-7 TR1 cells (Figure 3c ). In addition, data obtained from MTT (Figure 3d upper panel) as well as soft-agar (Figure 3d lower panel) growth assays revealed that CDCA treatment inhibited EGF-induced growth by 70% in anchorage-dependent and 50% in anchorageindependent assays in MCF-7 TR1 cells. CDCA was less effective in MCF-7 cells. These results well correlated with the downregulatory effect of CDCA on EGFinduced cyclin D1 expression, particularly in MCF-7 TR1 cells (Figure 3e ).
Activated FXR inhibits the binding of NF-kB to HER2 promoter region To explore whether HER2 downregulation relies on transcriptional mechanisms, we evaluated, using realtime reverse transcription (RT)-PCR, HER2 mRNA levels after treatment with CDCA for different times. Exposure to CDCA exhibited a time-dependent reduction in HER2 mRNA levels in both MCF-7 and MCF-7 TR1 cells (Figure 4a ). Also, transcriptional activity of a reporter plasmid containing the human HER2 promoter region (pNeuLite) was significantly reduced with CDCA treatment in both cell lines (Figures 4c and d) .
The human HER2 promoter contains multiple consensus sites for several transcription factors, including Sp1, as well as activator protein (AP)-1 and NF-kB, the well known effectors of FXR transrepression (He et al., 2006; Vavassori et al., 2009) (Figure 4b ). To identify the region within the HER2 promoter responsible for CDCA inhibitory effects, HER2 promoter-deleted construct (À232 pNeuLite) activity was tested ( Figure 4b ). We observed that the responsiveness to CDCA was still maintained, suggesting that the region from À232 to þ 1 containing the NF-kB motif might be involved in transrepression mechanisms exerted by activated FXR (Figures 4c and d) . Thus, we performed site-directed mutagenesis on the NF-kB domain (NF-kB Mut) within the HER2 promoter ( Figure 4b ). Mutation of this domain abrogated CDCA effects (Figures 4c and d) . These latter results demonstrate that the integrity of NF-kB-binding site is necessary for FXR modulation of HER2 promoter activity in breast cancer cells.
The specific role of the NF-kB motif in the transcriptional regulation of HER2 by CDCA was investigated using electrophoretic mobility shift assays. We observed the formation of a complex in nuclear extracts from MCF-7 and MCF-7 TR1 cells using synthetic oligodeoxyribonucleotides corresponding to the NF-kB motif ( Figure 5a , lanes 1 and 5), which was abrogated by incubation with 100-fold molar excess of unlabeled probe ( Figure 5a , lanes 2 and 6), demonstrating the specificity of the DNA-binding complex. This inhibition was no longer observed when mutated oligodeoxyribonucleotide was used as competitor ( Figure 5a, lanes 3 and 7) . Interestingly, treatment with CDCA strongly decreased the DNA-binding protein complex compared with Figures 1a and b) . To better define the role of FXR in the inhibition of NF-kB binding on HER2 promoter, a competition assay using recombinant NF-kB protein and increasing amounts of in vitrotranslated FXR protein (1, 3 and 5 ml) was carried out. A dose-dependent reduction in the NF-kB complex was seen ( Figure 5c , lanes 1-4), suggesting that physical interaction between these two transcription factors may inhibit the binding of NF-kB to human HER2 promoter region. To further test this possibility, we performed coimmunoprecipitation studies using nuclear protein fractions from MCF-7 and MCF-7TR1 cells treated with CDCA. As shown in Figure 6a , the formation of an FXR and NF-kB complex was detected in untreated cells, and this association was enhanced with FXR ligand treatment. Moreover, to confirm the involvement of NF-kB in CDCA-mediated HER2-downregulation at the promoter level, ChIP assays were performed. Using specific antibodies against NF-kB and RNA-polymerase II, protein-chromatin complexes were immunoprecipitated from cells cultured with or without CDCA for 1 h. The resulting precipitated DNA was then quantified using real-time PCR with primers spanning the NF-kB-binding element in the HER2 promoter region. NF-kB recruitment was significantly decreased upon CDCA treatment in both cell lines (Figure 6b ). This result was well correlated with a lower association of RNA-polymerase II to the HER2 regulatory region (Figure 6c) . To further confirm the transcriptional repression mediated by activated FXR, we also evaluated the histone deacetylase 3 association on the NF-kB-responsive sequence within the HER2 promoter. CDCA stimulation enhanced the recruitment of histone deacetylase 3 to this NF-kB promoter site (Figure 6d ).
HER2 downregulation underlies the ability of FRX ligands to inhibit breast cancer cell growth
We evaluated the effects of CDCA on cell growth in the ERa-negative and HER2-overexpressing breast cancer cells SKBR3. Treatment with CDCA inhibited SKBR3 anchorage-dependent growth in a dose-dependent Figure 5 Electrophoretic mobility shift assay of the NF-kB-binding site in the HER2 promoter region. (a) Nuclear extracts from MCF-7 and MCF-7 TR1 cells were incubated with a double-stranded NF-kB specific sequence probe labeled with [g 32 P]ATP and subjected to electrophoresis in a 6% polyacrylamide gel (lanes 1 and 5). Competition experiments were performed adding as competitor a 100-fold molar excess of unlabeled probe (lanes 2 and 6) or a 100-fold molar excess of unlabeled oligonucleotide containing a mutated NF-kB RE (lanes 3 and 7) . Lanes 4 and 8, nuclear extracts from CDCA (50 mM) -treated MCF-7 and MCF-7 TR1 cells, respectively, incubated with probe. Lane 9, NF-kB protein. Lane 10, probe alone. (b) Nuclear extracts from MCF-7 and MCF-7 TR1 cells were incubated with a double-stranded NF-kB specific sequence probe labeled with [g 32 P]ATP (lanes 1 and 7) or with a 100-fold molar excess of unlabeled probe (lanes 2 and 8). Nuclear extracts incubated with anti-NF-kB (lanes 3 and 9) or IgG (lanes 4 and 10). 
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C Giordano et al manner ( Figure 7a ) and reduced colony growth in anchorage-independent assay (Figure 7b ). Indeed, we found, after 48 h of treatment with CDCA, a marked decrease in both HER2 protein and mRNA levels (Figures 7c and d) . In these cells, HER2 promoter activity was similarly reduced with CDCA treatment (Figure 7e ). Finally, we explored the ability of FXR ligands to inhibit proliferation using as additional model Tam-resistant derivative cell line engineered to stably overexpress HER2 (MCF-7/HER2-18). As expected, Tam-resistant growth in these cells was not affected by both CDCA and GW4064 treatments (Figure 7f) . Altogether, these results well evidence how FXRmediated downregulation of HER2 at transcriptional level is fully responsible for inhibiting breast cancer cell proliferation.
Discussion
In this study, we show for the first time that the activated FXR downregulates HER2 expression in ERa-positive breast cancer cells resistant to Tam. This occurs through the inhibition of NF-kB binding to its responsive element located in the human HER2 promoter region and results in a significant reduction of Tam-resistant growth.
The HER2/neu transmembrane kinase receptor is a signaling amplifier of the HER family network, as activation of membrane tyrosine receptors (EGFR, HER3 and HER4) by their respective ligands determines the formation of homodimeric and heterodimeric kinase complexes into which this receptor is recruited as a preferred partner (Yarden, 2001) . Multiple lines of evidences suggest a role of HER2 in the pathogenesis of breast carcinoma (Allred et al., 1992; Glockner et al., 2001) , and clinical data suggest that breast tumors expressing elevated levels of HER2 show a more aggressive phenotype and worse outcome when treated with Tam (Arpino et al., 2004; De Laurentiis et al., 2005) . Thus, inhibitory agents targeting HER2, such as the monoclonal antibody trastuzumab (herceptin), have been explored to improve hormonal treatment or delay emergence of endocrine resistance in estrogen-dependent breast tumors (Johnston, 2009 ). However, even though an increased response rate is obtained when trastuzumab is used in combination with chemotherapeutic agents (Seidman et al., 2001; Slamon et al., 2001) , patients can still develop resistance (Slamon et al., 2001 ). These observations highlight the importance of discovering new therapeutic tools interfering with HER2-driven signaling to overcome therapy resistance.
We have demonstrated that treatment of breast cancer cells resistant to Tam with the FXR natural ligand CDCA resulted in a reduction of HER2 protein expression. Similar results were also obtained in the ERa-negative and HER2-overexpressing SKBR3 breast cancer cells, suggesting that it may represent a general mechanism not related to cell specificity. Moreover, it assumes more relevance in Tam-resistant breast cancer cells, which are strongly dependent on HER2 activity for their growth. The complete abrogation of FXRmediated HER2 downregulation with expression of an FXR-DN vector, along with the effects exerted by the synthetic FXR agonist GW4064, clearly demonstrated that activated FXR is involved in the regulation of HER2 expression. Furthermore, quantitative RT-PCR analysis demonstrated that HER2 mRNA levels were significantly decreased in both MCF-7 and MCF-7 TR1 cells treated with CDCA, suggesting that the FXRinduced HER2 downregulation arises via transcriptional mechanisms. Therefore, we focused on the molecular mechanisms by which FXR mediates repression of HER2 gene expression and on the biological consequences of FXR activation on anti-estrogen-resistant growth of breast cancer cells.
FXR acts mainly by regulating the expression of target genes by binding either as a monomer or heterodimer with the retinoid X receptor to FXR response elements (Laffitte et al., 2000; Ananthanarayanan et al., 2001; Claudel et al., 2002; Kalaany and Mangelsdorf, 2006) . Human HER2 promoter did not display any FXR response elements, thus it is reasonable to hypothesize that FXR-induced downregulation of HER2 promoter activity may occur through its interaction with other transcriptional factors. For instance, it (a) MCF-7 and MCF-7 TR1 cells were treated with vehicle (À) or CDCA 50 mM for 1 h before lysis. FXR protein was immunoprecipitated using an anti-FXR polyclonal antibody (IP:FXR) and resolved in SDS-polyacrylamide gel electrophoresis. Immunoblotting was performed using an anti-NF-kB (p65 subunit) monoclonal antibody and anti-FXR antibody. MCF-7 and MCF-7 TR1 cells were treated in the presence of vehicle (À) or CDCA 50 mM for 1 h, then crosslinked with formaldehyde, and lysed. The precleared chromatin was immunoprecipitated with anti-NF-kB (b), anti-RNA polymerase II (c) and anti-HDCA3 (d) antibodies. A 5 ml volume of each sample and input was analyzed by real-time PCR using specific primers to amplify HER2 promoter sequence, including the NF-kB site. Similar results were obtained in multiple independent experiments. *Po0.01 compared with vehicle.
has been described the transrepression mechanisms for FXR-mediated inhibition of endothelin-1 expression in vascular endothelial cells (He et al., 2006) . In addition, it has also been demonstrated that FXR negatively regulates IL-1b expression by stabilizing the nuclear corepressor NCoR on the NF-kB sequence within the IL-1b promoter (Vavassori et al., 2009) . Several recognition elements are present within the HER2 proximal promoter (Ishii et al., 1987; Hurst, 2001) and among these functional motifs we have identified both AP-1 and NF-kB response elements as potential targets of FXR. We have demonstrated by functional studies and site-specific mutagenesis analysis that the integrity of the NF-kB sequence is a prerequisite for the downregulatory effects of the FXR ligand on HER2 promoter activity. These results were supported by electrophoretic mobility shift assays, which revealed a marked decrease in a specific DNA-binding complex in nuclear extracts from MCF-7 and MCF-7 TR1 cells treated with CDCA. In vitro competition studies showed that FXR protein was able to inhibit the binding of NF-kB to its consensus site on the HER2 promoter. Furthermore, we observed a reduced recruitment of both NF-kB and RNA polymerase II in CDCA-treated cells, concomitant with an enhanced recruitment of histone deacetylase 3 supporting a negative transcriptional role for FXR in modulating HER2 expression.
The physiological relevance of these effects is pointed out by proliferation studies showing that FXR activation reduced breast cancer cell growth, but did not affect (Knowlden et al., 2003; Nicholson et al., 2004) . Our studies showed that CDCA treatment significantly reduced the ability of EGF to activate its signal transduction cascade in MCF-7 TR1 cells, inhibiting both HER2 and MAPK phosphorylation. In addition, FXR activation was associated with a marked inhibition in EGF-induced growth, concomitant with a reduction in cyclin D1 expression in Tam-resistant breast cancer cells. All together these data demonstrate, as represented in Figure 8 , that activated FXR, by preventing the binding of NF-kB to its response element located in the HER2 promoter sequence, abrogates HER2 expression and signaling, resulting in an inhibition of Tam-resistant growth in breast cancer cells.
Deciphering the molecular mechanisms responsible for the development of hormonal resistance is essential for establishing the most appropriate hormone agent according to tumor characteristics and for defining the optimal sequence of endocrine therapies. Moreover, this knowledge is critical for development of new therapeutic approaches able to either overcome or prevent endocrine resistance in breast cancer patients. Over the last years, significant survival benefits for breast cancer were derived from the use of combined treatment of endocrine therapies with new targeted therapies in endocrine responsive breast cancer (Johnston, 2009) . In this scenario, the sequencing or the combination of Tam with FXR ligands may represent an important research issue to explore as an alternative therapeutic strategy to treat breast cancer patients whose tumors exploit HER2 signaling to escape Tam treatment.
Materials and methods
Reagents and antibodies
The following components were obtained from the given respective companies, with their addresses in brackets. DMEM, L-glutamine, penicillin, streptomycin, fetal bovine serum, MTT, 4-hydroxytamoxifen, CDCA and EGF from Sigma (Milan, Italy). TRIzol by Invitrogen (Carlsbad, CA, USA). (Xing et al., 2000) . The FXR-responsive reporter gene (FXRE-IR1) and FXR-DN expression plasmids were provided from Dr T.A. Kocarek (Institute of Environmental Health Sciences, Wayne State University, USA) (Kocarek et al., 2002) .
The À232 pNeuLite construct was generated by PCR using as template the pNeuLite plasmid with the following primers: forward 5 0 -GATAAGTGTGAGAACGGCTGCAGGC-3 0 and reverse 5 0 -GGGCAGATCTGGTTTTCCGGTCCCAAT GGA-3 0 . The amplified DNA fragment was digested with BglII and KpnI and ligated into pGL2-basic vector. Deletion was confirmed by DNA sequencing.
Site-directed mutagenesis
The pNeuLite promoter plasmid-bearing NF-kB-responsive element-mutated site (NF-kB mut) was created by site-directed mutagenesis using Quick Change kit (Stratagene, La Jolla, CA, USA), according to manufacturer's method. We used as template the pNeuLite plasmid and the following primers (mutations are shown as lowercase letters): 5 0 -AGAGAGGG AGAAAGTGAAGCTaatcGTTGCCGACTCCCAGACTTC G-3 0 and 5 0 -CGAAGTCTGGGAGTCGGCAACgattAGC TTCACTTTCTCCCTCTCT-3 0 . Mutation was confirmed by DNA sequencing.
Cell culture MCF-7 cells were cultured in DMEM containing 10% fetal bovine serum. MCF-7 TR1 and MCF-7 TR2 cells were generated in the laboratory of Dr Fuqua as previously described (Barone et al., 2011) and maintained with 10 À6 M (MCF-7 TR1) and 10 À7 M (MCF-7 TR2) of 4-hydroxytamoxifen. SKBR3 cells were cultured in phenol red-free RPMI medium containing 10% fetal bovine serum. MCF-10A normal breast epithelial cells were grown in DMEM-F12 medium containing 5% horse serum. MCF-7/HER2-18 were kindly provided by Dr Schiff (Baylor College of Medicine, Houston, TX, USA) and maintained as described . Before each experiment, cells were grown in phenol redfree medium, containing 5% charcoal-stripped fetal bovine serum for 2 days and treated as described.
Cell proliferation assays
Cell proliferation was assessed using MTT and soft-agar anchorage-independent growth assays as described (Barone et al., 2009; Giordano et al., 2010) . The IC 50 values were calculated using GraphPad Prism 4 (GraphPad Software Inc., San Diego, CA) as described (Herynk et al., 2006) .
Immunoprecipitation and immunoblot analysis
Cells were treated as indicated before lysis for total protein extraction (Catalano et al., 2010) . Nuclear extracts were prepared as described (Morelli et al., 2004) . For coimmunoprecipitation experiments, we used 1 mg of nuclear protein extract and 2 mg of FXR antibody, followed by protein A/G precipitation. Equal amounts of cell extracts and coimmunoprecipitated protein were subjected to SDS-polyacrylamide gel electrophoresis, as described (Catalano et al., 2010) .
RT-PCR and Real-time RT-PCR assays FXR gene expression was evaluated by the RT-PCR method using a RETROscript kit. The cDNAs obtained were amplified using the following primers: forward 5 0 -CGAGCCTGAAG AGTGGTACTGTC-3 0 and reverse 5 0 -CATTCAGCCAACA TTCCCATCTC-3 0 (FXR); forward 5 0 -CTCAACATCTCCC CCTTCTC-3 0 and reverse 5 0 -CAAATCCCATATCCTCGT-3 0 (36B4).
The PCR was performed for 35 cycles for hFXR (94 1C 1 min, 65 1C 1 min, 72 1C 1 min) and 18 cycles for 36B4 (94 1C for 1 min, 58 1C for 1 min and 72 1C for 1 min), as described (Catalano et al., 2010) .
HER2 gene expression was evaluated by real-time RT-PCR. Total RNA was reverse transcribed with the RETROscript kit; 5 ml of diluted (1:3) cDNA was analyzed in triplicates by realtime PCR in an iCycler iQ Detection System (Bio-Rad) using SYBR Green Universal PCR Master Mix, following the manufacturer's recommendations. Each sample was normalized on its GAPDH mRNA content. Primers used for the amplification were: forward 5 0 -CACCTACAACACAGACAC GTTTGA-3 0 and reverse 5 0 -GCAGACGAGGGTGCAGGA T-3 0 (HER2); forward 5 0 -CCCACTCCTCCACCTTTGAC-3 0 and reverse 5 0 -TGTTGCTGTAGCCAAATTCGTT-3 0 (GAPDH). The relative gene expression levels were calculated as described (Sirianni et al., 2007) .
Transient transfection assays MCF-7 and MCF-7 TR1 cells were transiently transfected using the FuGENE 6 reagent with FXR reporter gene (FXRE-IR1) in the presence or absence of FXR-DN plasmid. In a set of experiments, MCF-7, MCF-7 TR1 and SKBR3 cells were transfected with different HER2 promoter constructs. Luciferase activity was assayed as described (Catalano et al., 2010) .
Electrophoretic mobility shift assays Nuclear extracts from cells, treated or not for 3 h with CDCA, were prepared as described (Andrews and Faller, 1991) . The DNA sequences used as probe or as cold competitors are the following (nucleotide motifs of interest are underlined and mutations are shown as lowercase letters): NF-kB, 5 0 -AA GTGAAGCTGGGAGTTGCCGACTCCCAGA-3 0 ; mutated NF-kB, 5 0 -AAGTGAAGCTaatcGTTGCCGACTCCCAGA-3 0 ; AP-1, 5 0 -AGGGGGCAGAGTCAC CAGCCTCTG-3 0 ; mutated AP-1, 5 0 -AGGGGGCAtcaTCACCAGCCTCTG-3 0 ; Sp1 5 0 -ATCCCGGACTCCGGGGGAGGGGGC-3 0 ; mutated Sp1, 5 0 -ATCCCGGACCTCattG GGAGGGGGC-3 0 . In vitro-transcribed and -translated FXR protein was synthesized using the T7 polymerase in the rabbit reticulocyte lysate system. Probe generation and the protein-binding reactions were carried out as described (Catalano et al., 2010) . For experiments involving anti-NF-kB (p65) antibody, the reaction mixture was incubated with this antibody at 4 1C for 12 h before addition of labeled probe.
Chromatin immunoprecipitation assays
Cells were treated with CDCA or left untreated for 1 h and then DNA/protein complexes were extracted as described (Catalano et al., 2010) . The precleared chromatin was immunoprecipitated with anti-NF-kB (p65), anti-histone deacetylase 3 or anti-polymerase II antibodies. A normal mouse serum IgG was used as negative control. A 5 ml volume of each sample and input DNA was used for real-time PCR using the primers flanking NF-kB sequence in the human HER2 promoter region: 5 0 -TGAGAACGGCTGCAGGCA AC-3 0 and 5 0 -CCCACCAACTGCATTCCAA-3 0 . Real-time PCR was performed as described above. Final results were calculated using the DDCt method, using input Ct values instead of the GAPDH mRNA. The basal sample was used as calibrator.
Statistical analyses
Each datum point represents the mean ± s.d. of three different experiments. Data were analyzed by Student's t-test using the GraphPad Prism 4 software program. Po0.05 was considered as statistically significant.
